Genetic and clinical correlates of entosis in pancreatic ductal adenocarcinoma

被引:46
|
作者
Hayashi, Akimasa [1 ,2 ]
Yavas, Aslihan [1 ,3 ]
McIntyre, Caitlin A. [1 ,2 ]
Ho, Yu-jui [4 ]
Erakky, Amanda [1 ]
Wong, Winston [5 ]
Varghese, Anna M. [5 ]
Melchor, Jerry P. [1 ,2 ]
Overholtzer, Michael [6 ]
O'Reilly, Eileen M. [1 ,5 ]
Klimstra, David S. [1 ,3 ]
Basturk, Olca [3 ]
Iacobuzio-Donahue, Christine A. [1 ,2 ,3 ]
机构
[1] Mem Sloan Kettering Canc Ctr, David M Rubenstein Ctr Pancreat Canc Res, Sloan Kettering Inst, 1275 York Ave, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Canc Biol & Genet Program, 1275 York Ave, New York, NY 10021 USA
[5] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
[6] Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Cell Biol Program, 1275 York Ave, New York, NY 10021 USA
关键词
D O I
10.1038/s41379-020-0549-5
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Entosis is a type of regulated cell death that promotes cancer cell competition. Though several studies have revealed the molecular mechanisms that govern entosis, the clinical and genetic correlates of entosis in human tumors is less well understood. Here we reviewed entotic cell-in-cell (CIC) patterns in a large single institution sequencing cohort (MSK IMPACT clinical sequencing cohort) of more than 1600 human pancreatic ductal adenocarcinoma (PDAC) samples to identify the genetic and clinical correlates of this cellular feature. After case selection, 516 conventional PDACs and 21 ASCs entered this study and similar to 45,000 HPFs (median 80 HPFs per sample) were reviewed; 549 entotic-CICs were detected through our cohort. We observed that entotic-CIC occurred more frequently in liver metastasis compared with primary in PDAC. Moreover, poorly differentiated adenocarcinoma or adenosquamous carcinoma had more entotic-CIC than well or moderately differentiated adenocarcinoma. With respect to genetic features TP53 mutations, KRAS amplification, and MYC amplification were significantly associated with entosis in PDAC tissues. From a clinical standpoint entotic CICs were independently associated with a poor prognosis by multivariate Cox regression analysis when considering all cases or primary PDACs specifically. These results provide a contextual basis for understanding entosis in PDAC, a highly aggressive cancer for which molecular insights are needed to improve survival.
引用
收藏
页码:1822 / 1831
页数:10
相关论文
共 50 条
  • [41] Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study
    Kung, Heng-Chung
    Yu, Jun
    MEDCOMM, 2023, 4 (02):
  • [42] Biological and Clinical Impacts of Glucose Metabolism in Pancreatic Ductal Adenocarcinoma
    Liu, Zhao
    Hayashi, Hiromitsu
    Matsumura, Kazuki
    Uemura, Norio
    Shiraishi, Yuta
    Sato, Hiroki
    Baba, Hideo
    CANCERS, 2023, 15 (02)
  • [43] Clinical features of cystatin A expression in patients with pancreatic ductal adenocarcinoma
    Komura, Takuya
    Takabatake, Hisashi
    Harada, Kenichi
    Yamato, Masatoshi
    Miyazawa, Masaki
    Yoshida, Keiko
    Honda, Masao
    Wada, Takashi
    Kitagawa, Hirohisa
    Ohta, Tetsuo
    Kaneko, Shuichi
    Sakai, Yoshio
    CANCER SCIENCE, 2017, 108 (11): : 2122 - 2129
  • [44] Circadian Genes in Pancreatic Ductal Adenocarcinoma: Alterations and Clinical Correlations
    Relles, Daniel
    Chipitsyna, Galina
    Hyslop, Terry
    Yeo, Charles J.
    Arafat, Hwyda A.
    GASTROENTEROLOGY, 2012, 142 (05) : S1041 - S1042
  • [45] Clinical significance of MUC13 in pancreatic ductal adenocarcinoma
    Khan, Sheema
    Zafar, Nadeem
    Khan, Shabia S.
    Setua, Saini
    Behrman, Stephen W.
    Stiles, Zachary E.
    Yallapu, Murali M.
    Sahay, Peeyush
    Ghimire, Hemendra
    Ise, Tomoko
    Nagata, Satoshi
    Wang, Lei
    Wan, Jim Y.
    Pradhan, Prabhakar
    Jaggi, Meena
    Chauhan, Subhash C.
    HPB, 2018, 20 (06) : 563 - 572
  • [46] Clinical Features of Trousseau Syndrome Associated With Pancreatic Ductal Adenocarcinoma
    Kusaka, H.
    Yoshida, K.
    Nakashima, Y.
    Aoki, H.
    Tokioka, S.
    Nishimon, R.
    Kitagawa, A.
    Hino, K.
    PANCREAS, 2019, 48 (10) : 1469 - 1469
  • [47] Genomic Heterogeneity of Pancreatic Ductal Adenocarcinoma and Its Clinical Impact
    Gutierrez, Maria Laura
    Munoz-Bellvis, Luis
    Orfao, Alberto
    CANCERS, 2021, 13 (17)
  • [48] Clinical Relevance of Cancerization of Ducts in Resected Pancreatic Ductal Adenocarcinoma
    Kinny-Koester, Benedict
    Ahmad, Yembur
    Pflueger, Michael J.
    Habib, Joseph R.
    Fujikura, Kohei
    Hutchings, Danielle
    Cameron, John L.
    Shubert, Christopher R.
    Lafaro, Kelly J.
    Burkhart, Richard A.
    Burns, William R.
    Javed, Ammar A.
    Yu, Jun
    Hruban, Ralph H.
    Wood, Laura D.
    Thompson, Elizabeth D.
    He, Jin
    PANCREAS, 2024, 53 (06) : e528 - e536
  • [49] Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma
    Skorupan, Nebojsa
    Dominguez, Mayrel Palestino
    Ricci, Samuel L.
    Alewine, Christine
    CANCERS, 2022, 14 (17)
  • [50] Pancreatic Ductal Adenocarcinoma, β-blockers, and Antihistamines: A Clinical Trial Is Needed
    Baker, Jillian G.
    Sloan, Erica K.
    Pfleger, Kevin D. G.
    Mccormick, Peter J.
    Salmeron, Cristina
    Insel, Paul A.
    FUNCTION, 2025, 6 (01):